论文部分内容阅读
内皮抑素是目前已知作用最强最专一的内源性血管形成抑制因子[1],它是首个进入人临床试验的内源性血管生成抑制剂。本研究通过检测肺癌患者化疗前后血清内皮抑素水平的变化,探讨其对肺癌的诊断、化疗疗效及预后评估的价值。1临床资料70例原发性肺癌均为2004年2月~2007年5月住院
Endostatin is the most potent and most specific endogenous inhibitor of angiogenesis known [1] and is the first endogenous angiogenesis inhibitor to enter human clinical trials. In this study, by detecting the changes of serum endostatin levels in patients with lung cancer before and after chemotherapy, to explore the diagnosis of lung cancer, chemotherapy efficacy and prognosis of the value. 1 Clinical data 70 cases of primary lung cancer were from February 2004 to May 2007 hospitalization